Projected 2018 sales:
$1.521 billion
2012 sales: $64 million

Drugs like Revlimid and Velcade dominate the multiple myeloma market, but that didn't mean there was no room for Kyprolis when Onyx ($ONXX) launched it last July. Kyprolis was approved for patients who have been treated with at least two other medications, with analysts forecasting north of $1.5 billion in peak sales--$900 million in the U.S. with another $600 million coming from Europe.

Not long afterward, however, Celgene ($CELG) maneuvered its way into Onyx's arena to compete directly with Kyprolis, gaining approval for Pomalyst in February of this year for patients with multiple myeloma that has already resisted two or more other treatments. Celgene announced it would be pricing Pomalyst at $10,500 per month, just a shade above the $9,950 charged monthly for Kyprolis.

But Kyprolis and Pomalyst aren't necessarily mutually exclusive. One analyst said he expected doctors to move patients between the two drugs, in some cases prescribing a combination of the two, thus enhancing the sales of both.

Special Report: Onyx Pharmaceuticals - Buyout Buzz: The most frequently cited takeover targets in biotech

For more:
Analysis: A long lineup of potential buyers crowds Onyx picture
Flush with cash, Onyx Pharma shops for new drugs
New Celgene drug packs punch for multiple myeloma market
Onyx wins accelerated approval for myeloma drug Kyprolis


Suggested Articles

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.

With a new target date approaching for its competitor to Lantus, the FDA has again given Biocon’s insulin manufacturing plant in Malaysia a once over.

Despite outcomes data that left analysts less-than-enthused, Eli Lilly's Trulicity scored the FDA's nod to lower CV risks in a first-ever approval.